{"DataElement":{"publicId":"2724621","version":"1","preferredName":"Prior Hormonal Therapy Administered Type","preferredDefinition":"Text name(s) of hormonal therapy administered to an individual before enrollment in a clinical trial. [Manually-curated]","longName":"PRIOR_HORM_TX_TP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2188728","version":"1","preferredName":"Prior Hormonal Therapy Administered","preferredDefinition":"information related to prior hormonal therapy administered.","longName":"PRIOR_HORMONALTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206567","version":"1","preferredName":"Prior Hormone Therapy","preferredDefinition":"Earlier in time or order.:Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C25629:C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FA31-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E54DEC97-5F79-61C9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2724614","version":"1","preferredName":"Hormonal Therapy Type","preferredDefinition":"Treatment that adds, blocks, or removes hormones.  For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels.  To slow or stop the growth of certain cancers (such as prostate and breast cancer), hormones may be given to block the body's natural hormones.  Sometimes surgery is needed to remove the source of hormones._Type; a subdivision of a particular kind of thing.","longName":"HORM_TX_TP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4463B177-14F7-3505-E044-0003BA3F9857","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2008-01-23","deletedIndicator":"No"},{"value":"None","valueDescription":"No other hormonal therapies","ValueMeaning":{"publicId":"2724615","version":"1","preferredName":"No other hormonal therapies","longName":"2724615","preferredDefinition":"No other hormonal therapies","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4463B177-1503-3505-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4463B177-151C-3505-E044-0003BA3F9857","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2008-01-23","deletedIndicator":"No"},{"value":"AI + Fas + OS","valueDescription":"Aromatase Inhibitor plus Faslodex plus Ovarian Suppression","ValueMeaning":{"publicId":"2724616","version":"1","preferredName":"Aromatase Inhibitor plus Faslodex plus Ovarian Suppression","longName":"2724616","preferredDefinition":"Aromatase Inhibitor plus Faslodex plus Ovarian Suppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4463B177-1528-3505-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4463B177-1541-3505-E044-0003BA3F9857","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2008-01-23","deletedIndicator":"No"},{"value":"Fas + OS","valueDescription":"Faslodex plus Ovarian Suppression","ValueMeaning":{"publicId":"2724617","version":"1","preferredName":"Faslodex plus Ovarian Suppression","longName":"2724617","preferredDefinition":"Faslodex plus Ovarian Suppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4463B177-154D-3505-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4463B177-1566-3505-E044-0003BA3F9857","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2008-01-23","deletedIndicator":"No"},{"value":"Fas","valueDescription":"Faslodex (SERD)","ValueMeaning":{"publicId":"2724618","version":"1","preferredName":"Faslodex (SERD)","longName":"2724618","preferredDefinition":"Faslodex (Selective Estrogen Receptor Down-Regulator)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4463B177-1572-3505-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4463B177-158B-3505-E044-0003BA3F9857","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2008-01-23","deletedIndicator":"No"},{"value":"AI + OS","valueDescription":"Aromatase Inhibitor plus Ovarian Suppression","ValueMeaning":{"publicId":"2724619","version":"1","preferredName":"Aromatase Inhibitor plus Ovarian Suppression","longName":"2724619","preferredDefinition":"Aromatase Inhibitor plus Ovarian Suppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4463B177-1597-3505-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4463B177-15B0-3505-E044-0003BA3F9857","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2008-01-23","deletedIndicator":"No"},{"value":"AI","valueDescription":"Aromatase inhibitor","ValueMeaning":{"publicId":"2571015","version":"1","preferredName":"Aromatase inhibitor","longName":"2571015","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E274-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"ALAIS","dateModified":"2007-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4463B177-15C5-3505-E044-0003BA3F9857","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2008-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2724613","version":"1","preferredName":"Hormone Therapy Type","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.:Type; a subdivision of a particular kind of thing.","longName":"C15445:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4463B16E-C7AB-2F1A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"ONEDATA","dateModified":"2008-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4463B16E-C7BC-2F1A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812731","version":"1","longName":"U Washington","context":"NCIP"},{"publicId":"2812732","version":"1","longName":"FES Study","context":"NCIP"},{"publicId":"2812734","version":"1","longName":"U Washington New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other hormonal therapies","type":"Preferred Question Text","description":"Other hormonal therapies","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"4463BB90-F381-4208-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-23","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":"Curated to support U Washington adoption of C3D for FES trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}